PIPELINE

South Rampart’s proprietary compounds have the potential to provide relief for patients with many types of pain including chronic, acute post-operative and emergency room and neuropathic pain. South Rampart Pharma is working with top medicinal chemists to develop oral and intravenous formulations optimized for each indication. Based on preclinical and IND-enabling studies, SRP compounds have broad potential applicability in a number of different pain indications.

South Rampart Pharma - Pipeline

South Rampart Pharma will begin the first Phase 1 trial in January 2022. Check back here for more updates on the clinical status of SRP compounds and for details about participating in one of our clinical trials.